Changes in the molecular nodes of the Notch and NRF2 pathways in cervical cancer tissues from the precursor stages to invasive carcinoma.
cervical cancer
gene expression in cervical cancer
signal transduction pathways
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Nov 2024
Nov 2024
Historique:
received:
28
03
2024
accepted:
24
06
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
13
9
2024
Statut:
epublish
Résumé
Cancer is a multifactorial disease characterized by the loss of control in the expression of genes known as cancer driver genes. Cancer driver genes trigger uncontrolled cell replication, which leads to the development of malignant tumors. A cluster of signal transduction pathways that contain cancer driver genes involved in cellular processes, such as cell proliferation, differentiation, apoptosis and dysregulated organ growth, are associated with cancer initiation and progression. In the present study, three signal transduction pathways involved in cervical cancer (CC) development were analyzed: The Hippo pathway (FAT atypical cadherin, yes-associated protein 1, SMAD4 and TEA domain family member 2), the Notch pathway [cellular-MYC, cAMP response element-binding binding protein (CREBBP), E1A-associated cellular p300 transcriptional co-activator protein and F-Box and WD repeat domain containing 7] and the nuclear factor erythroid 2-related factor 2 (NRF2) pathway [NRF2, kelch-like ECH-associated protein 1 (KEAP1), AKT and PIK3-catalytic subunit α]. Tumor samples from patients diagnosed with various stages of CC, including cervical intraepithelial neoplasia (CIN) 1, CIN 2, CIN 3,
Identifiants
pubmed: 39268158
doi: 10.3892/ol.2024.14655
pii: OL-28-5-14655
pmc: PMC11391250
doi:
Types de publication
Journal Article
Langues
eng
Pagination
522Informations de copyright
Copyright: © Limones-Gonzalez et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cell Chem Biol. 2021 Apr 15;28(4):503-514.e12
pubmed: 33400925
Curr Oncol. 2021 Jul 29;28(4):2868-2880
pubmed: 34436017
Signal Transduct Target Ther. 2022 Nov 8;7(1):376
pubmed: 36347846
Geroscience. 2023 Jun;45(3):1889-1898
pubmed: 36856946
Cell Death Dis. 2023 Nov 4;14(11):719
pubmed: 37925449
J Cell Biol. 2003 Nov 24;163(4):723-8
pubmed: 14638857
Ther Adv Chronic Dis. 2020 Sep 18;11:2040622320957143
pubmed: 32994913
Antioxidants (Basel). 2022 Mar 11;11(3):
pubmed: 35326187
Cancers (Basel). 2023 Feb 14;15(4):
pubmed: 36831561
Cancers (Basel). 2023 Jul 02;15(13):
pubmed: 37444578
Cancer Res. 2021 Feb 15;81(4):847-859
pubmed: 33509944
Int J Mol Sci. 2022 Feb 05;23(3):
pubmed: 35163748
Trends Mol Med. 2023 Jul;29(7):554-566
pubmed: 37076339
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Nucleic Acids Res. 2020 Jan 8;48(D1):D77-D83
pubmed: 31665515
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
J Hematol Oncol. 2021 Aug 21;14(1):128
pubmed: 34419139
Biotechnol Appl Biochem. 2022 Feb;69(1):248-264
pubmed: 33442914
Antioxid Redox Signal. 2023 May;38(13-15):974-988
pubmed: 36930785
Pathol Res Pract. 2016 Aug;212(8):678-85
pubmed: 27161306
EBioMedicine. 2022 Jan;75:103756
pubmed: 34942444
Cancer Sci. 2020 May;111(5):1829-1839
pubmed: 32162442
Histochem Cell Biol. 2008 Sep;130(3):435-45
pubmed: 18679706
J Hematol Oncol. 2023 May 2;16(1):45
pubmed: 37131214
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Lancet Glob Health. 2023 Feb;11(2):e197-e206
pubmed: 36528031
Cell Death Dis. 2023 Sep 4;14(9):587
pubmed: 37666813
Oncol Lett. 2019 Oct;18(4):3423-3432
pubmed: 31516560
Sci Rep. 2023 Sep 1;13(1):14359
pubmed: 37658132
Semin Cancer Biol. 2022 May;80:1-17
pubmed: 31866476
Nat Rev Cancer. 2020 Oct;20(10):555-572
pubmed: 32778778
Cancer Rep (Hoboken). 2021 Aug;4(4):e1369
pubmed: 33822486
Nat Metab. 2020 Apr;2(4):318-334
pubmed: 32691018